MONDAY, SEPTEMBER 09, 2019Therm★‌→↔o Fisher Scientific to £day announced an agreement ×÷with Eli Lilly and Company for develop©≈ment of a companion diagn∞♦↑ostic that will use the U.S Food and Drug Admini♣ stration-approved, next-generation sequenc€"" ing-based Oncomine Dx T≠™✔λarget Test to identify ceπ≥≤™rtain non-small cell lung c>γ↓ancer (NSCLC) and thyroid cancer pati≤→ents who may be treated wi™♣♦th Lilly's investigational therapy, LOXO£₹★-292. Specifically, the test "€would be used with patients whose tumors   harbor a rearranged during transfection (εδRET) alteration. RET variants areσ> found in about two percent of NSC&‌LC, about 60 percent of medullary thyroid≥←★€ cancer (MTC) and up to approx✘™imately 20 percent of other thyroid cance±→ rs.LOXO-292 is a highly selective and potent or§$al RET inhibitor being studied by Lil₹≤≤ly in a Phase 1/2 clinical trial for the trea♣&§tment of advanced cancers that harbor activating £ alterations of the RE≠↔T kinase. Changes in the RET kina₩λ>se, including fusions and mut‍$$ations, can cause uncontrolled cell growth l✘Ω€✘eading to tumor development. Can¥$<δcers driven by such alterations a¥&♣re mostly dependent on this singularly activate©¥×d pathway, making them highly susceptibleγβ to small molecule inhibitors."One of the bigge±"☆ st barriers to realizing the full p™©ower of precision medicine Ω¥in oncology is having access to high-quality tesσ¶ting, such as next-generation sequencin♦&×<g-based tests, that identify a λ ♥broad range of clinically actio→®nable alterations, can be performed lo→₩‌₩cally and allow treating institutions to pa‌ rticipate in this important✔'§¶ step in the evolving ∑→>treatment paradigm," said Anne White, pres¥₩↕​ident of Lilly Oncology. "With th¶δis agreement, we believe that more patients wi♥ £ll gain access to high-qualit≤δΩ÷y tumor profiling, identifying those wit•​≈←h RET alterations potentially suitable ✘δfor LOXO-292 therapy, in addition to o"✔'‍ther alterations sui§¥☆table for treatment wit£™✘h other therapies."Mark Stevenson, executiveφ ©σ vice president and chief operating office>§¶r of Thermo Fisher Scien↔λtific said: "We are pleased♦‍ to enter into this agreement with Lill£‌>Ωy and leverage our Oncomine platform as a means≤∞∑ to quickly identify cancer§→ε✘ patients who may benefit ↔π from this breakthrough therapy, ev☆®✔±en in cases of limited sample avai↓φ≈lability. We are commi♥×÷tted to working with our global pharmaceutic•  al partners to help b✘¥♦ring forth next-generation sequencing★"↑€-based companion diagnostics and b×≥₹est-in-class therapies that can have a profound÷§♥✘ impact on treating cancer patients."Undeγ↔↑€r the terms of the agreement, Th​≠←ermo Fisher will ret£<εain the rights to commercialize the test in al∏↑← l markets, including the'≥★ United States, Europe₩β"​ and Japan. Once validat™←$♠ion is complete, Thermo Fisher will s↓₹Ωubmit a supplemental premarket approval (sPMA&•¥) application to the U.S→∑. Food and Drug Administratio≥∏n (FDA) to broaden the c®₽€linical claims of its Oncomine Dx Tε∞γ‍arget Test.The NGS test, which receive•∞☆&d FDA approval in 2017, φ‌γ↕simultaneously screens tumor sampleγγ‌©s for multiple gene variants assoc✔ ∞×iated with NSCLC, a subset of which are ut¶¶§≤ilized to identify pat↔γients who may be eligible for severa♥∞↕l approved targeted therapies. It is€↕ covered in the United State★∏↔s by the Centers for Medicare & M∞↔'πedicaid Services and a majority ¥βσof the largest commerci♦π$ al U.S. health plans. Oncomine Dλ x Target Test is also approvδ₽♠δed for reimbursement by the Japan Mi​"σnistry of Health, Labor an∑¥♥d Welfare (MHLW).2019 Asia-pacifiΩ$c pharma IP Leader Summi​βt: http://en.zenseegroup.com/p/510934•≤₹'/ will be held in Beijing  onπ≠‍< November 14-15, and will attract more ™>than 500 industry experts from domestic and fo©↔♦✔reign pharmaceutical companies,÷¥ε biotechnology companies,÷" governments, associations<φ , law firms, intellectual property ag§•ents and other compani±&‍€es to attend.Official re®σgistration and consultation chann♦∏els:Contact：AnnPhone: 021-65650305Email：Ma$δ"<rketing@zenseegroup.comhttp:/γ€±'/en.zenseegroup.com/p/510934/